Here's Why Halozyme Therapeutics (HALO) is a Strong Value Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Halozyme Therapeutics (HALO) is a Top-Ranked Growth Stock: Should You Buy?
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
3 Reasons Why Growth Investors Shouldn't Overlook Halozyme Therapeutics (HALO)
Halozyme Therapeutics (HALO) could produce exceptional returns because of its solid growth attributes.
Why Halozyme Therapeutics (HALO) is a Top Value Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Halozyme Therapeutics: Q1 Earnings Reveal A Bigger And Deeper Moat
Halozyme Therapeutics reported strong Q1 2025 earnings with a 35% revenue increase, 54% net income growth, and raised full-year guidance, reinforcing its status as a top biotech growth story. Key growth drivers include the ENHANZE portfolio with new blockbuster drugs, a robust clinical pipeline, and next-gen delivery systems, ensuring sustained royalty growth and competitive advantage. Despite potential risks like the Keytruda SC litigation and pharma tariffs, Halozyme's strong balance sheet, rising free cash flow, and share buybacks boost EPS and shareholder value.
Halozyme Therapeutics (HALO) is a Great Momentum Stock: Should You Buy?
Does Halozyme Therapeutics (HALO) have what it takes to be a top stock pick for momentum investors? Let's find out.
Why Halozyme Therapeutics (HALO) is a Top Momentum Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
HALO Stock Up on Q1 Earnings and Revenue Beat, Raised 2025 View
Halozyme reports better-than-expected first-quarter 2025 results. The company increases revenue guidance for 2025.
Halozyme Therapeutics (HALO) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates
Although the revenue and EPS for Halozyme Therapeutics (HALO) give a sense of how its business performed in the quarter ended March 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Halozyme Therapeutics (HALO) Surpasses Q1 Earnings and Revenue Estimates
Halozyme Therapeutics (HALO) came out with quarterly earnings of $1.11 per share, beating the Zacks Consensus Estimate of $0.95 per share. This compares to earnings of $0.79 per share a year ago.
Halozyme Therapeutics: Still Undervalued Ahead Of Earnings
Halozyme Therapeutics, Inc. remains a buy due to its strong subscription-based business model, high growth, and undervaluation. HALO's robust product library, focused on drug delivery systems, positions it well to avoid sector issues and continue outperforming the market. The company has shown consistent revenue growth, high gross margins, and strong returns on investments, with a fair value estimated at $67.71.
Halozyme Therapeutics (HALO) Earnings Expected to Grow: Should You Buy?
Halozyme Therapeutics (HALO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
